Vidhyayana - ISSN 2454-8596
An International Multidisciplinary Peer-Reviewed E-Journal
www.vidhyayanaejournal.org
Indexed in: Crossref, ROAD & Google Scholar

42

A Study on Artificial Intelligence and its Role in Redefining Alzheimer's Disease Diagnostics

Pooja Rathod

Assistant Professor,

Sardar Patel College of Engineering

Jigisha Trivedi

Assistant Professor,

Sardar Patel College of Engineering

Abstract:

This study Examines the use of 'Artificial intelligence (AI)' in developing revolutionary diagnostic approaches for Alzheimer's Disease (AD). Given the rising incidence of AD and the critical need for early and accurate diagnosis, AI presents promising solutions through advanced data analysis and pattern recognition.[1] This research reviews recent advancements in AI methodologies, including Deep learning frameworks, Convolutional Neural Networks (CNN), and explainable AI (XAI), applied to multimodal medical imaging such as MRI and PET scans. The study examines various datasets, evaluation metrics, and future directions in AI-based diagnostics, emphasizing the potential for integrating volumetric analysis, hyperparameter optimization, and multi-class classification to enhance diagnostic precision. The findings indicate that AI has the capability to significantly improve early detection, classification, and progression prediction of AD, offering valuable insights for clinical applications and the development of new therapeutic strategies.[12]

Key word: AD (Alzheimer's Disease), CNN (Convolutional Neural Networks) MRI (Magnetic resonance imaging), PET (Positron Emission Tomography)

Introduction:

Alzheimer's disease (AD) is a progressive cognitive impairment that results from the death of healthy brain cells. It is the most frequent cause of dementia, which impairs social and mental capacities and makes day-to-day living more difficult. This results from shrinking brain tissue, the formation of neurofibrillary tangles and amyloid plaques, and the death of brain cells. The World Health Organization estimates that there will be 55 million cases of dementia worldwide in 2021; by 2030, there will be 78 million cases, and by 2050, there will be 139 million cases. Most people over 65 are at high risk of dementia, but only 3% of younger people get it, often due to different diseases. If AD isn't treated early, it can severely damage brain cells responsible for thinking and memory, leading to loss of brain function, language problems, and difficulty with logical thinking. As the disease progresses, patients struggle with basic daily activities.

Early diagnosis of AD is crucial because it worsens over time. AD can be diagnosed when symptoms appear or by using brain scans before symptoms start. This early stage, called "preclinical AD," can last for years without noticeable symptoms. Modern imaging can detect amyloid beta deposits, a protein linked to AD, even without symptoms. Detecting these deposits early can help in clinical trials and future treatments.[3]



Fig 1: Normal vs Alzheimer Brain

https://www.alamy.com/stock-photo/normal-and-alzheimer-disease-brain.html?sortBy=relevant

Treatment of AD:

In treating Alzheimer's disease (AD), deep learning (DL) plays a crucial role, especially with models like Transformer. This DL model can handle various kinds of data sequences and lengths, capturing detailed features effectively. For instance, researchers used graph neural networks to study drug molecules, focusing on AD-related targets like ApoE. By searching databases like KEGG and PubChem, they created drug-target interaction data to extract molecular structure details. Then, they utilized Transformer networks to merge these features from different layers, predicting potential AD therapeutics.[8] Amyloid-beta 42 (Aβ-42) is a key factor in AD development. To gauge drug effectiveness, another study screened the PubChem compound library using deep neural networks. They identified potential Aβ-42 inhibitors and evaluated their impact on AD by observing their effects on Aβ-42 levels. These approaches highlight the potential of DL in identifying and developing treatments for AD.



Fig :2 Different Imaging Techniques for AD Diagnosis [2]

Literature Review:

- Arafa et al. review the application of deep learning (DL) methods for neuroimaging-based early Alzheimer's disease (AD) identification. For the diagnosis of AD, imaging techniques including PET and MRI are frequently utilized. Convolutional neural networks (CNNs), in particular, have demonstrated great accuracy in the classification of AD, MCI, and healthy patients among several DL models. Preprocessing techniques like intensity normalization, noise reduction, and brain extraction are crucial for improving image quality. However, challenges such as data availability, class imbalance, and the "black box" nature of DL models hinder progress. Data augmentation and transfer learning are employed to overcome some of these issues. While the potential of DL is clear, future research should focus on improving data sharing, model interpretability, and the integration of multimodal data for more accurate and reliable AD detection.[2]
- Castellano et al. provide a strategy for "Automated Detection of Alzheimer's Disease: A Multi-Modal Approach with 3D MRI and Amyloid PET," which is a study on the use of deep learning for the multimodal detection of Alzheimer's disease (AD) that focuses on MRI and amyloid PET scans. The study highlights that multi-modal model outperform uni-modal ones due to the complementary nature of the data. Using CNN models, the authors demonstrate that 3D imaging techniques provide better feature extraction and classification performance. The models were trained on the OASIS-3 dataset, with results showing that combining MRI and PET scans significantly improves diagnostic accuracy, achieving up to 95% accuracy with multi-modal fusion. The paper also emphasizes the importance of explain in AI models, utilizing Grad-CAM to identify critical brain regions involved in AD, such as the temporal and frontal lobes. The research suggests that integrating different imaging modalities can enhance the early diagnosis of AD. [3]
- A more precise CNN architecture for the early detection and classification of Alzheimer's disease is provided by Hasan, M. E. et al. A novel convolutional neural network (CNN) model for identifying and categorizing Alzheimer's disease (AD) is proposed using MRI data. MRI data is utilized by the architecture to categorize patients into several phases of Alzheimer's disease (AD), such as moderate cognitive impairment (MCI) and normal cognition (NC). Two CNN networks with various filter sizes make up the model; these

networks are concatenated at the classification layer. Improvements in feature extraction yield remarkable classification accuracy rates of 99.43%, 99.57%, and 99.13% for 3-way, 4-way, and 5-way classification tasks, respectively, thanks to this method. The research highlights the model's ability to effectively capture both local and global brain patterns, aiding in early AD diagnosis. Additionally, techniques like Grad-CAM were used for interpretability, making the model useful for clinical applications. The paper emphasizes the importance of multi-class classification for accurate AD staging and the model's potential for real-world medical use.[4]

- Mahim, S. M., et al. offer a novel method for identifying Alzheimer's disease (AD) that combines a Gated Recurrent Unit (GRU) model with a Vision Transformer (ViT). This hybrid model offers better accuracy than traditional models in the analysis and classification of AD stages from brain MRI data. Essential features from MRI images are extracted by the ViT, and sequential dependencies are captured by the GRU to improve the predictive power of the model. The authors validate their approach using three datasets, achieving classification accuracies of up to 99.69% for binary tasks and 99.26% for multi-class tasks. The study also integrates Explainable AI (XAI) techniques, such as LIME, SHAP, and Attention Maps, to provide interpretability and help clinicians understand the model's decision-making process. This transparency aids in clinical adoption, offering a promising tool for early and accurate AD diagnosis.[8]
- Peixin Lu et. al introduces a novel AI model for early detection of Alzheimer's Disease (AD) by predicting the conversion of Mild Cognitive Impairment (MCI) to AD. The study emphasizes the importance of combining multiple data types such as MRI, genetic, and clinical data to improve prediction accuracy. The authors propose the 'Hierarchical Attention-Based Multimodal Fusion (HAMF)' framework, which uses attention mechanisms to assign different weights to each modality and dynamically learns interactions between them. The model outperforms existing methods, achieving 87.2% accuracy and an AUC of 0.913. Clinical data is highlighted as the most influential modality. The study also uses SHAP to enhance model interpretability, helping clinicians understand the decision-making process, with the framework intended to assist in AD detection and future research.[7]

- Luyao Wang et al introduces a novel approach to Alzheimer's disease (AD) diagnosis. It emphasizes the role of brain glucose metabolism and hemodynamic changes in understanding AD. By using hybrid PET/MRI imaging and combining metabolic and functional connectomes, the study proposes a sparse coupling method to extract early-stage AD imaging markers. The study involves participants from healthy control, subjective cognitive decline (SCD), and cognitive impairment (CI) groups. It finds that this sparse coupling method is more effective in capturing early-stage AD markers, particularly in brain regions like the default mode and limbic networks. The method outperforms traditional markers in classification accuracy, especially in distinguishing between SCD and healthy controls. The results show that metabolic-functional coupling could provide critical insights into early AD diagnosis and disease progression tracking, offering a significant tool for clinical application.[12]
- Amar Shukla et al. combine two imaging modalities, magnetic resonance imaging (MRI) and positron emission tomography (PET), to improve the accuracy of Alzheimer's disease (AD) identification. The research combines functional and structural brain data using a multimodal image fusion technique. The study uses an ensemble classification method to distinguish between participants with AD, subjects with mild cognitive impairment (MCI), and subjects with cognitive normalcy (CN) after features are extracted from these fused images. Specifically, Gradient Boosting and Support Vector Machine (SVM) are combined. The results indicate a high accuracy in binary classification tasks, achieving 99% accuracy in distinguishing between AD vs. CN and MCI vs. CN, and 91% for AD vs. MCI. With respect to multi-class classification (AD, MCI, CN), the model's 96% accuracy is impressive. When used with machine learning methods, the combination of PET and MRI images improves detection and classification performance over single-modality methods. This study is especially helpful for enhancing Alzheimer's disease early diagnosis and therapy planning.[10]

- Odosami et al. used MRI and PET imaging to identify Alzheimer's disease (AD). An early diagnosis is essential for Alzheimer's disease (AD), a degenerative brain ailment that affects memory and cognitive abilities. In order to train a modified ResNet18 deep learning model for binary classification that is, to distinguish between early-stage moderate cognitive impairment (EMCI) and late-stage MCI (LMCI) the study suggests a novel strategy for combining MRI and PET scans. The suggested model using the ADNI database achieves a classification accuracy of 73.90% with the use of multimodal input fusion. To further add interpretability to the algorithm's decisions, the study offers an Explainable AI (XAI) model to explain the deep learning outcomes. The method demonstrates that fusing structural data from MRI with functional data from PET improves diagnostic accuracy and could serve as a robust tool for early AD detection. The approach highlights the benefits of combining neuroimaging data to provide complementary insights into AD progression.[9]

Discussion:

The research landscape in automated detection and diagnosis of Alzheimer's Disease showcases a diverse array of methodologies and datasets, emphasizing the importance of innovative approaches in tackling this complex condition. From deep learning frameworks utilizing CNNs to explainable AI techniques like XAI, these studies leverage various modalities such as MRI, PET, and fused data to enhance accuracy and interpretability. Future directions underscore the necessity of refining existing methods through techniques like hyperparameter optimization and integrating multi-class classification for different disease stages. Additionally, there's a clear emphasis on validation across larger, more diverse datasets and exploring clinical applicability to bridge the gap between research and real-world practice. By identifying imaging biomarkers and enhancing classification capabilities, these endeavors aim to not only improve diagnostic accuracy but also pave the way for the development of novel therapies and interventions in Alzheimer's Disease.

Conclusion:

In conclusion, the utilization of artificial intelligence (AI) in revolutionary diagnostic approaches for Alzheimer's disease represents a promising frontier in the quest for early detection and effective management of this debilitating condition. Through the application of diverse AI methodologies, ranging from deep learning frameworks to ensemble classifiers and explainable AI techniques, researchers are making significant strides in automating the detection and classification of Alzheimer's disease using various modalities such as MRI, PET, and fused data. The insights gained from these studies not only enhance our understanding of the disease but also offer practical solutions for improving diagnostic accuracy and clinical decision-making. Moreover, the emphasis on future directions, including the integration of multi-modal data, validation across larger datasets, and exploration of clinical applicability, underscores the commitment to translating research findings into tangible benefits for patients and healthcare practitioners alike. As AI continues to evolve and mature, its role in revolutionizing diagnostic approaches for Alzheimer's disease holds immense promise in advancing early intervention, personalized treatment, and ultimately, improving outcomes for individuals affected by this challenging neurological disorder.

Acknowledgement:

I would like to express my gratitude to my family for their unwavering support. I also thank Sardar Patel College of Engineering for providing the necessary resources. Finally, I acknowledge my colleagues for their contributions, which greatly helped in the success of this work

Conflict of Interest

The authors explicitly states that they have no conflicting interests in ‘A study on Artificial Intelligence and its Role in Redefining Alzheimer’s Disease Diagnostics.’

References

[1] Arafa, D. A., Moustafa, H. E. D., Ali, H. A., & Ali-Eldin, A. M. T. (2024). A deep learning framework for early diagnosis of Alzheimer's disease on MRI images. *Multimedia Tools and Applications*, 83(2). Springer US. https://doi.org/10.1007/s11042-023-15738-7

[2] Arafa, D. A., Moustafa, H. E. D., Ali-Eldin, A. M. T., & Ali, H. A. (2022). Early detection of Alzheimer's disease based on the state-of-the-art deep learning approach: A comprehensive survey. *Multimedia Tools and Applications*.

[3] Castellano, G., Esposito, A., Lella, E., Montanaro, G., & Vessio, G. (2024). Automated detection of Alzheimer's disease: A multi-modal approach with 3D MRI and amyloid PET. *Scientific Reports, 14*(1), 1–10. https://doi.org/10.1038/s41598-024-56001-9

[4] El-Assy, A. M., Amer, H. M., Ibrahim, H. M., & Mohamed, M. A. (2024). A novel CNN architecture for accurate early detection and classification of Alzheimer's disease using MRI data. *Scientific Reports, 14*(1), 1–19. https://doi.org/10.1038/s41598-024-53733-6

[5] Hasan, M. E., & Wagler, A. (2024). New convolutional neural network and graph convolutional network-based architecture for AI applications in Alzheimer's disease and dementia-stage classification. *Ai, 5*(1), 342–363. https://doi.org/10.3390/ai5010017

[6] Jack, C. R., & Holtzman, D. M. (2013). Biomarker modeling of Alzheimer's disease. *Neuron, 80*(6), 1347-1358.

[7] Lu, P., Hu, L., Mitelpunkt, A., Bhatnagar, S., Lu, L., & Liang, H. (2024). A hierarchical attention-based multimodal fusion framework for predicting the progression of Alzheimer's disease. *Biomedical Signal Processing and Control, 88*, 105669. https://doi.org/10.1016/j.bspc.2023.105669

[8] Mahim, S. M., et al. (2023). Unlocking the potential of XAI for improved Alzheimer's disease detection and classification using a ViT-GRU model. *IEEE Access, 12*, 8390–8412. https://doi.org/10.1109/ACCESS.2024.3351809

[9] Odusami, M., Maskeliūnas, R., Damaševičius, R., & Misra, S. (2023). Explainable deep-learning-based diagnosis of Alzheimer's disease using multimodal input fusion of PET and MRI images. *Journal of M edical and Biological Engineering, 43*(3), 291–302. https://doi.org/10.1007/s40846-023-00801-3

[10] Shukla, A., Tiwari, R., & Tiwari, S. (2023). Alzheimer's disease detection from fused PET and MRI modalities using an ensemble classifier. *Machine Learning and Knowledge Extraction, 5*(2), 512–538. https://doi.org/10.3390/make5020031

[11] Sorour, S. E., El-Mageed, A. A. A., Albarrak, K. M., Alnaim, A. K., Wafa, A. A., & El-Shafeiy, E. (2024). Classification of Alzheimer's disease using MRI data based on deep learning techniques. *Journal of King Saud University - Computer and Information Sciences, 36*(2), 101940. https://doi.org/10.1016/j.jksuci.2024.101940

[12] Wang, L., et al. (2023). A metabolism-functional connectome sparse coupling method to reveal imaging markers for Alzheimer's disease based on simultaneous PET/MRI scans. *Human Brain Mapping, 44*(17), 6020–6030. https://doi.org/10.1002/hbm.26493